|Chemical and physical data|
|Molar mass||390.4 g/mol g·mol−1|
|3D model (JSmol)|
Chidamide (Epidaza) is a histone deacetylase inhibitor (HDI) developed wholly in China. It was also known as HBI-8000. It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10.
Chidamide is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL), and has orphan drug status in Japan.[better source needed] As of April 2015[update] it is only approved in China.
- "China's First Homegrown Pharma". April 2015.
- HUYA Bioscience International Grants An Exclusive License For HBI-8000 In Japan And Other Asian Countries To Eisai. Feb 2016
- Qiao, Z (2013-04-26). "Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells". Biochem Biophys Res Commun. 434 (1): 95–101. doi:10.1016/j.bbrc.2013.03.059. PMID 23541946.
- Guha, Malini (2015-04-01). "HDAC inhibitors still need a home run, despite recent approval". Nature Reviews Drug Discovery. 14 (4): 225–226. doi:10.1038/nrd4583. PMID 25829268.
- Wang, Shirley S. (2015-04-02). "A New Cancer Drug, Made in China". The Wall Street Journal. Retrieved 13 April 2015.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|